Researchers at UT Southwestern have discovered a potential “Achilles’ heel” in ovarian cancer cells, and a new biomarker that may open up more avenues for targeted therapies. The study, published in the journal Cell, was led by W. Lee Kraus, PhD, Professor of Obstetrics and Gynecology and Pharmacology at UT Southwestern. Sridevi Challa, PhD, a … Continued
Sultry summer days can make anyone feel lazy and daydream of faraway places. But at OCRA, we’re working as hard as ever to fulfill our dream of a day when no one need fear an ovarian cancer diagnosis. Check out all that’s happening and discover ways that you can get involved. RESEARCH ADVOCACY PATIENT SUPPORT … Continued
A study published in the American Journal of Obstetrics & Gynecology provides new insight into previously established research that oral contraceptive use is connected to lower ovarian cancer risk in the general population, by more closely examining the link among BRCA1 and BRCA2 mutation carriers. Scientists have long known that oral contraceptive use, particularly long-term … Continued
A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations–and is effective even in tumors that have become resistant to PARP inhibitors. BRCA1 … Continued
“It’s kind of like how the Apollo mission to the moon gave us Velcro.” Dr. David Chapel and his team are laying new groundwork in better understanding the origins of high-grade serous carcinoma, even if the exact applications are hard to see this early on. David, an OCRA grantee, speaks with great passion when he … Continued
Before we head into the long holiday weekend, we wanted to share all the latest news and happenings. See below for updates in ovarian cancer research and advocacy, and discover new ways to get support and get involved. RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
New research from The Wistar Institute and Peter MacCallum Cancer Center has uncovered a previously unknown checkpoint mechanism for gene expression, that may open up new avenues for transcription-based targeted cancer therapies in the future. This exciting study, published in the cancer journal Cell, was made possible in part by an OCRA research grant to … Continued
Results from a large British clinical trial, which involved more than 200,000 post-menopausal women who were followed for more than 15 years, showed that screening average-risk, asymptomatic women for ovarian cancer does not reduce deaths from the disease. The results were published in the British medical journal, The Lancet. The trial, called the UK Collaborative Trial of … Continued
The first part of this year’s annual meeting of the AACR was titled “Discovery Science Driving Clinical Breakthroughs” and was held virtually from April 10 to 14, 2021. Two OCRA Research Advocates, Elise Daniel and Annie Ellis (a member of OCRA’s Scientific Advisory Committee), participated in the Scientist<->Survivor Program (SSP), which is designed to build … Continued
2021 SGO Virtual Meeting Themes This year’s Society of Gynecologic Oncology annual meeting was held virtually, with most sessions held March 19 to 21, 2021. The majority of sessions included pre-recorded abstract presentations followed by dynamic and engaging live Q&A. In addition to the latest research in gynecologic cancers highlighted below, several sessions included timely … Continued
Flowers are blooming all around us, people are beginning to rediscover the things that matter most, and every day, OCRA grantees are making strides in understanding even more about ovarian cancer. Happy (almost!) May! RESEARCH ADVOCACY PATIENT SUPPORT & PROGRAMS EVENTS WAYS TO GIVE
Every year, more than 22,000 people are diagnosed with ovarian cancer. Most (85% – 90%) will be diagnosed with a form of epithelial ovarian cancer; and among these, most will be high-grade serous ovarian cancer (HGSOC). Though HGSOC is the most common type of ovarian cancer, there are several different types and subtypes of the … Continued
Get email updates about research news, action alerts, and ways to join the fight.
